Skip to main content
Premium Trial:

Request an Annual Quote

Illumina s Q2 loss widens to 25 cents a share, falling short of expectations

NEW YORK, Sept 11 - Genomics company Illumina (Nasdaq: ILMN) reported Monday pro forma net losses of $5.3 million, or 25 cents a share, for the company’s fiscal second quarter, compared with losses of $1.1 million, or nine cents a share in the year ago period.

Wall Street had expected the San Diego-based company to post losses of 20 cents a share, based on a survey of two analysts conducted by First Call/Thomson Financial.

Revenues for the quarter slipped 39 percent in the second quarter to $79 million from $130 million a year ago.

The results reflect the conversion of preferred stock into common stock, which took place in July. Excluding the conversion, the company had losses of $2.05 cents a share, compared with 95 cents a share a year ago.

Net losses for the six-month period ended June 30, 2000 were $10.1 million, compared with net losses of $2.0 million, in the six month period of 1999. On a pro forma basis the loss per share was 48 cents for first half 2000, compared with 15 cents in the year ago period.

Illumina develops tools for the large-scale analysis of genetic variation and function. The company hopes that these tools and the information garnered from them will enable the development of personalized medicine.

Illumina was down 1 1/16, or 2.5 percent, at 41 7/8 in late afternoon trading.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.